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Ian O. Ellis2 and Robert I. Nicholson1Correction
After the publication of this work [1], an error was no-
ticed in Fig. 2b and Fig. 4b as well as Fig. 5d. and Fig.
5d. Images of the ERK1/2 blots were accidentally dupli-
cated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2
was mistakenly cropped out of the final image. The ori-
ginal blot for Fig. 4b., “total EGFR” (or lane 2) is shown
below to avoid any misunderstanding of the data. We
apologize for this error, which did not affect any of the
interpretations or conclusions of the article.
Fig. 4b. Uncropped original blot of “total EGFR” sug-
gests that total EGFR levels increase with gefitinib treat-
ment. However, increases in EGFR expression in
response to gefitinib, are not seen across the study,
which would suggest this increase is simply an anomaly.
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